Back to search

Article

Genomic and Transcriptomic Correlates of Response to Tarlatamab in Small Cell Lung Cancer

2026-02-06

Abstract excerpt

<h4>Purpose</h4> Tarlatamab is a DLL3-directed bispecific T-cell engager demonstrating clinically meaningful activity in relapsed small cell lung cancer (SCLC) in the phase II DeLLphi-301 trial. Determinants of tarlatamab sensitivity and resistance are incompletely understood, and thus we sought to identify genomic and transcriptional correlates of tarlatamab sensitivity using a clinical sequencing pipeline at a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0ca76d82-6f04-562c-ab3d-9de63b351187
DOI
10.64898/2026.01.30.26344966
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genomic and Transcriptomic Correlates of Response to Tarlatamab in Small Cell Lung CancerDOI 10.64898/2026.01.30.26344966
Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung CancerSemantic proximity
SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic SignaturesSemantic proximity
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerSemantic proximity
Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity
Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future PerspectivesSemantic proximity
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity
Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy.Semantic proximity
SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signaturesSemantic proximity
SCLC TumorMiner: A Genomics Platform for Small Cell Lung Cancer Precision OncologySemantic proximity
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerSemantic proximity
Single‐cell multi‐omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK‐positive lung cancerSemantic proximity
The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancerSemantic proximity
Select a neighboring publication to make it the new centre.